The role of TRIM37 in driving tumorigenesis and cancer-specific vulnerability to PLK4 inhibition
TRIM37 在驱动肿瘤发生和癌症特异性对 PLK4 抑制的脆弱性中的作用
基本信息
- 批准号:10624789
- 负责人:
- 金额:$ 49.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-06-01 至 2027-05-31
- 项目状态:未结题
- 来源:
- 关键词:17q17q23Automobile DrivingBiogenesisBreastBreast Cancer CellCell Cycle ProgressionCell ProliferationCell divisionCellsCentrosomeChemicalsChromosome SegregationClinicClinicalCollaborationsCoupledDataDefectDevelopmentDown-RegulationExhibitsFailureFunctional disorderGene AmplificationGenesGeneticGenomeGenomic InstabilityGenomicsGoalsHeterogeneityHumanHypersensitivityInheritedMalignant NeoplasmsMammary NeoplasmsMediatingMicrotubule-Organizing CenterMicrotubulesMitoticMitotic spindleModelingMolecularMutationNeuroblastomaOncogenesOncogenicOrganellesOrganoidsPLK1 genePPM1D genePhosphoric Monoester HydrolasesPhosphotransferasesPoly(ADP-ribose) Polymerase InhibitorPre-Clinical ModelPrimary NeoplasmProliferatingPropertyProteinsReportingRoleTP53 geneTestingTherapeuticTumor PromotionWorkaurora B kinasebrca genecancer cellcancer therapycell killingeffectiveness testinggenetic approachgenetic manipulationimaging approachinhibitorloss of function mutationmalignant breast neoplasmneoplastic cellnovelnovel therapeuticsoverexpressionpatient derived xenograft modelpharmacologicpreservationprotein expressionsynthetic lethal interactiontumortumorigenesisubiquitin ligaseubiquitin-protein ligase
项目摘要
Project Summary
The concept of synthetic lethality has been validated clinically with the use of PARP inhibitors in treating
breast cancers with loss-of-function mutations in BRCA1/2. Nevertheless, only 5-10% of breast tumors are
caused by inherited mutations in BRCA1/2, highlighting a need to identify new synthetic lethal interactions that
can be exploited clinically. In this proposal, we capitalize on our recent discovery of a new synthetic lethal
interaction that is exposed by a cancer-specific genetic alteration.
Centrosomes are microtubule-organizing centers that catalyze the assembly of the mitotic spindle during cell
division. Centrosome duplication is tightly coupled to cell cycle progression and controlled by the master
regulatory kinase (Polo-like kinase 4) PLK4. Chemical inhibition of PLK4 activity leads to cell division in the
absence of centrosome duplication, producing centrosome-less cells that exhibit delayed mitotic spindle
assembly. Although most cancer cells can proliferate in the absence of centrosomes, we recently discovered
that inhibition of PLK4 leads to centrosome depletion that selectively triggers mitotic catastrophe in cancer cells
overexpressing TRIM37. This has therapeutic relevance as the TRIM37 chromosomal locus is amplified in 50-
60% of neuroblastomas and ~10% of breast cancers. In addition, amplification of this region is associated with
aggressive cancers with highly rearranged and unstable genomes. In this application, we will define how
TRIM37 overexpression promotes tumorigenesis and increases the vulnerability to PLK4 inhibitors. We will
also test the effectiveness of PLK4 inhibition in achieving selective killing of human cancer organoids
with TRIM37 amplification.
Aim 1 will determine how TRIM37 overexpression increases the sensitivity to PLK4 inhibitors and test if
TRIM37-driven centrosome dysfunction contributes to tumorigenesis by promoting mitotic errors. The 17q23
amplicon contains ~30 genes, including TRIM37 and the TP53-antagonizing phosphatase PPM1D. The
oncogenic properties of PPM1D overexpression have been validated in several models. Selective PPM1D
inhibitors have been developed, but how PPM1D cooperates with other genes encoded in the 17q23 amplicon
remains unknown. In Aim 2, we determine if PPM1D overexpression promotes TRIM37-mediated genomic
instability and test if PPM1D inhibition can potentiate the action of PLK4 inhibitors in these tumors. Finally, Aim
3 will examine if TRIM37 overexpression confers increased sensitivity to PLK4 inhibition in breast and
neuroblastoma tumor organoids. Understanding the role of TRIM37 in tumorigenesis will help define how its
overexpression drives the development of aggressive cancers and provide a rationale for the use of PLK4i in
the treatment of cancers with genomic amplification of TRIM37.
项目摘要
合成致命性的概念已经通过使用PARP抑制剂在临床上得到验证
具有BRCA1/2功能缺失突变的乳腺癌。然而,只有5%-10%的乳腺癌是
由BRCA1/2的遗传突变引起,突显出需要识别新的合成致死相互作用
可以在临床上利用。在这项提议中,我们利用了我们最近发现的一种新的合成致命物质
通过癌症特有的基因改变暴露出来的相互作用。
中心体是微管组织中心,在细胞过程中催化有丝分裂纺锤体的组装
组织。中心体复制与细胞周期进程紧密相连,并受主控器控制
调节蛋白激酶(Polo-like kinase4)Plk4。化学抑制Plk4活性导致细胞分裂
没有中心体复制,产生无中心体的细胞,表现出延迟的有丝分裂纺锤体
集合。虽然大多数癌细胞在没有中心体的情况下都能增殖,但我们最近发现
Plk4的抑制会导致中心体耗尽,从而选择性地触发癌细胞的有丝分裂灾难
过度表达TRIM37。这具有治疗意义,因为TRIM37染色体上的基因座在50%-
60%的神经母细胞瘤和约10%的乳腺癌。此外,该区域的扩增与
具有高度重排和不稳定基因组的侵袭性癌症。在本应用程序中,我们将定义
TRIM37过表达促进肿瘤发生,增加对Plk4抑制剂的易感性。我们会
还测试了Plk4抑制对人类癌症有机物的选择性杀伤效果
用TRIM37扩增。
AIM 1将确定TRIM37过表达如何增加对Plk4抑制剂的敏感性,并测试是否
TRIM37驱动的中心体功能障碍通过促进有丝分裂错误而促进肿瘤的发生。17q23
扩增子包含约30个基因,包括TRIM37和TP53-拮抗磷酸酶PPM1D。这个
PPM1D过度表达的致癌特性已在几个模型中得到验证。选择性PPM1D
已经开发出了抑制剂,但PPM1D如何与17q23扩增子中编码的其他基因合作
仍然不为人知。在目标2中,我们确定PPM1D的过度表达是否促进了TRIM37介导的基因组
不稳定和测试PPM1D抑制是否可以加强Plk4抑制剂在这些肿瘤中的作用。最后,瞄准
3将研究TRIM37的过度表达是否会增加乳房和乳房对Plk4抑制的敏感性
神经母细胞瘤,肿瘤细胞器。了解TRIM37在肿瘤发生中的作用将有助于确定它是如何
过度表达推动侵袭性癌症的发展,并为PLK4i的使用提供了理论基础
利用基因组扩增TRIM37基因治疗癌症。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sergi Regot其他文献
Sergi Regot的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sergi Regot', 18)}}的其他基金
The role of TRIM37 in driving tumorigenesis and cancer-specific vulnerability to PLK4 inhibition
TRIM37 在驱动肿瘤发生和癌症特异性对 PLK4 抑制的脆弱性中的作用
- 批准号:
10340029 - 财政年份:2022
- 资助金额:
$ 49.78万 - 项目类别:
Single Cell Analysis of MAPK Signaling Dynamics during Tissue Homeostasis
组织稳态过程中 MAPK 信号动力学的单细胞分析
- 批准号:
10669592 - 财政年份:2019
- 资助金额:
$ 49.78万 - 项目类别:
Single Cell Analysis of MAPK Signaling Dynamics during Tissue Homeostasis
组织稳态过程中 MAPK 信号动力学的单细胞分析
- 批准号:
10225574 - 财政年份:2019
- 资助金额:
$ 49.78万 - 项目类别:
Single Cell Analysis of MAPK Signaling Dynamics during Tissue Homeostasis
组织稳态过程中 MAPK 信号动力学的单细胞分析
- 批准号:
9797352 - 财政年份:2019
- 资助金额:
$ 49.78万 - 项目类别:
Single Cell Analysis of MAPK Signaling Dynamics during Tissue Homeostasis
组织稳态过程中 MAPK 信号动力学的单细胞分析
- 批准号:
10457101 - 财政年份:2019
- 资助金额:
$ 49.78万 - 项目类别:
Single Cell Analysis of MAPK Signaling Dynamics during Tissue Homeostasis
组织稳态过程中 MAPK 信号动力学的单细胞分析
- 批准号:
10579713 - 财政年份:2019
- 资助金额:
$ 49.78万 - 项目类别:
Single Cell Analysis of MAPK Signaling Dynamics during Tissue Homeostasis
组织稳态过程中 MAPK 信号动力学的单细胞分析
- 批准号:
10458556 - 财政年份:2019
- 资助金额:
$ 49.78万 - 项目类别:
相似海外基金
The role of TRIM37 in driving tumorigenesis and cancer-specific vulnerability to PLK4 inhibition
TRIM37 在驱动肿瘤发生和癌症特异性对 PLK4 抑制的脆弱性中的作用
- 批准号:
10340029 - 财政年份:2022
- 资助金额:
$ 49.78万 - 项目类别:
Project 1:Evolutionary dynamics and drivers of breast cancer metastasis and relapse
项目1:乳腺癌转移和复发的进化动力学和驱动因素
- 批准号:
10272389 - 财政年份:2021
- 资助金额:
$ 49.78万 - 项目类别:
Project 1:Evolutionary dynamics and drivers of breast cancer metastasis and relapse
项目1:乳腺癌转移和复发的进化动力学和驱动因素
- 批准号:
10704684 - 财政年份:2021
- 资助金额:
$ 49.78万 - 项目类别:
Project 3 Topological mapping of chromatin architectures for hormone-independent gene transcription
项目 3 激素非依赖性基因转录染色质结构的拓扑图
- 批准号:
9343416 - 财政年份:2017
- 资助金额:
$ 49.78万 - 项目类别:
Characterization of the Chromosome 17q23 Amplicon
染色体 17q23 扩增子的表征
- 批准号:
6473885 - 财政年份:2002
- 资助金额:
$ 49.78万 - 项目类别:
Characterization of the Chromosome 17q23 Amplicon
染色体 17q23 扩增子的表征
- 批准号:
6771091 - 财政年份:2002
- 资助金额:
$ 49.78万 - 项目类别:
Characterization of the Chromosome 17q23 Amplicon
染色体 17q23 扩增子的表征
- 批准号:
6624348 - 财政年份:2002
- 资助金额:
$ 49.78万 - 项目类别:
Characterization of the Chromosome 17q23 Amplicon
染色体 17q23 扩增子的表征
- 批准号:
6897199 - 财政年份:2002
- 资助金额:
$ 49.78万 - 项目类别:
Characterization of the Chromosome 17q23 Amplicon
染色体 17q23 扩增子的表征
- 批准号:
7071797 - 财政年份:2002
- 资助金额:
$ 49.78万 - 项目类别:
PHYSICAL MAPPING OF HUMAN CHROMOSOME 17Q23/Q24
人类染色体 17Q23/Q24 的物理图谱
- 批准号:
6107413 - 财政年份:1998
- 资助金额:
$ 49.78万 - 项目类别: